Joanne M. Donovan MD, PhD

Adjunct Clinical Associate Professor, Gastroenterology

72 E. Concord Street
Joanne Donovan



Medicine, MD, Harvard Medical School

Biomedical Engineering, PhD, Massachusetts Institute of Technology

Chemical Engineering, MS, Massachusetts Institute of Technology

Chemistry, BS, Massachusetts Institute of Technology


Published on 5/2/2019

Cowen L, Mancini M, Martin A, Lucas A, Donovan JM. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry. BMC Neurol. 2019 May 02; 19(1):84. PMID: 31046703.

Published on 1/1/2019

Finanger E, Vandenborne K, Finkel RS, Lee Sweeney H, Tennekoon G, Yum S, Mancini M, Bista P, Nichols A, Liu H, Fretzen A, Donovan JM. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-?B Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2019; 6(1):43-54. PMID: 30452422.

Published on 1/11/2017

Donovan JM, Zimmer M, Offman E, Grant T, Jirousek M. A Novel NF-?B Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol. 2017 05; 57(5):627-639. PMID: 28074489.

Published on 12/16/2014

Santos RD, Raal FJ, Donovan JM, Cromwell WC. Mipomersen preferentially reduces small low-density lipoprotein particle number inĀ patients with hypercholesterolemia. J Clin Lipidol. 2015 Mar-Apr; 9(2):201-9. PMID: 25911076.

Published on 10/11/2012

Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012 Nov 06; 126(19):2283-92. PMID: 23060426.

Published on 4/16/2012

Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UH, Nederveen AJ, Verheij J, Trip MD, Basart DC, Kastelein JJ, Stroes ES. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012 May; 33(9):1142-9. PMID: 22507979.

Published on 1/1/2010

Davidson MH, Donovan JM, Misir S, Jones MR. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2010; 10(5):305-14. PMID: 20860413.

Published on 11/1/2009

Handelsman Y, Abby SL, Jin X, Donovan JM, Jones MR. Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med. 2009 Nov; 121(6):62-9. PMID: 19940418.

Published on 1/1/2005

Donovan JM, Plone M, Dagher R, Bree M, Marquis J. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci. 2005; 1054:492-4. PMID: 16339704.

Published on 4/1/2002

Eckhardt ER, Wang DQ, Donovan JM, Carey MC. Dietary sphingomyelin suppresses intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers. Gastroenterology. 2002 Apr; 122(4):948-56. PMID: 11910347.

View full list of 12 publications.